Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview.

Published on Aug 6, 2021in Expert Review of Anticancer Therapy3.573
· DOI :10.1080/14737140.2021.1959319
Lothar Bergmann51
Estimated H-index: 51
(Praxis),
Sarah Weber4
Estimated H-index: 4
(Goethe University Frankfurt)
+ 1 AuthorsMarit Ahrens3
Estimated H-index: 3
(Goethe University Frankfurt)
Sources
Abstract
Introduction: Non-clear cell renal cell carcinoma (nccRCC) represents a highly heterogenous group of kidney cancer entities. As most clinical trials predominantly include patients with clear cell RCC (ccRCC), nccRCC treatment guidelines are mainly extrapolated from recommendations in ccRCC. Here, we review and elucidate current data on the pathologic classification and treatment of nccRCC.Areas covered: This article gives an overview of the WHO classification of RCC, showing the histological diversity of nccRCC and focusing particularly on entities first characterized since 2016, their specific molecular behavior and their role as indicators for hereditary cancer syndromes. In this context, we discuss the available data on nccRCC treatment oprtions such as tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, cytotoxic chemotherapy, and immune checkpoint inhibitors.Expert opinion: Although nccRCCs are relatively uncommon, entities of this type account for a subgroup of up to 20-25% of all RCCs. Advances in histopathology and molecular genetics, together with evidence gained from retrospective and prospective clinical data, have improved understanding of these tumors in recent years. Nevertheless, selective trials of current and novel therapies including new targeted agents in patients with nccRCC are urgently needed to further improve treatment guidelines.
📖 Papers frequently viewed together
20216.13Cancers
1 Citations
2017
4 Authors (Tian Zhang, ..., Sumanta K. Pal)
9 Citations
References90
Newest
2 CitationsSource
#4M. Martin (Complutense University of Madrid)H-Index: 8
5 CitationsSource
#1Toni K. Choueiri (Brigham and Women's Hospital)H-Index: 116
#2J.M.G. Larkin (The Royal Marsden NHS Foundation Trust)H-Index: 11
Last. Laurence Albiges (Institut Gustave Roussy)H-Index: 58
view all 19 authors...
Background Among patients with advanced renal cell carcinoma (RCC), those with sarcomatoid histology (sRCC) have the poorest prognosis. This analysis assessed the efficacy of avelumab plus axitinib versus sunitinib in patients with treatment-naive advanced sRCC. Methods The randomized, open-label, multicenter, phase III JAVELIN Renal 101 trial (NCT02684006) enrolled patients with treatment-naive advanced RCC. Patients were randomized 1 : 1 to receive either avelumab plus axitinib or sunitinib fo...
1 CitationsSource
#1Toni K. Choueiri (Brigham and Women's Hospital)H-Index: 116
#2Thomas Powles (QMUL: Queen Mary University of London)H-Index: 84
Last. Robert J. MotzerH-Index: 140
view all 31 authors...
Abstract Background The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known. ...
90 CitationsSource
#1Kiril Trpkov (U of C: University of Calgary)H-Index: 37
#2Ondrej Hes (Charles University in Prague)H-Index: 36
Last. Anthony J. Gill (Kolling Institute of Medical Research)H-Index: 73
view all 42 authors...
The Genitourinary Pathology Society (GUPS) reviewed recent advances in renal neoplasia, particularly post-2016 World Health Organization (WHO) classification, to provide an update on existing entities, including diagnostic criteria, molecular correlates, and updated nomenclature. Key prognostic features for clear cell renal cell carcinoma (RCC) remain WHO/ISUP grade, AJCC/pTNM stage, coagulative necrosis, and rhabdoid and sarcomatoid differentiation. Accrual of subclonal genetic alterations in c...
15 CitationsSource
#1Sumanta K. Pal (City of Hope National Medical Center)H-Index: 60
#2Catherine M. Tangen (Fred Hutchinson Cancer Research Center)H-Index: 63
Last. Primo N. Lara (UC Davis: University of California, Davis)H-Index: 72
view all 20 authors...
Summary Background MET (also known as hepatocyte growth factor receptor) signalling is a key driver of papillary renal cell carcinoma (PRCC). Given that no optimal therapy for metastatic PRCC exists, we aimed to compare an existing standard of care, sunitinib, with the MET kinase inhibitors cabozantinib, crizotinib, and savolitinib for treatment of patients with PRCC. Methods We did a randomised, open-label, phase 2 trial done in 65 centres in the USA and Canada. Eligible patients were aged 18 y...
26 CitationsSource
#1Robert J. MotzerH-Index: 140
#2Boris AlekseevH-Index: 28
Last. Toni K. ChoueiriH-Index: 116
view all 38 authors...
Abstract Background Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib ...
94 CitationsSource
#19Charles Schloss (MSD: Merck & Co.)H-Index: 9
#20Michael B. Atkins (Georgetown University)H-Index: 108
PURPOSEPembrolizumab, a programmed death 1 inhibitor, demonstrated promising single-agent activity in untreated patients with various cancer types. The phase II KEYNOTE-427 study evaluated efficacy...
19 CitationsSource
Abstract Background Chromophobe renal cell carcinoma (ChRCC) is a rare subtype of non-clear cell renal cell carcinoma. Due to its rarity, its molecular characterization as well as therapeutic targets are still not fully understood. Methods We performed a next-generation sequencing analysis using the platform Ion PGM System on 20 retrospectively collected ChRCC cases with the aim of identify molecular biomarkers with potential prognostic value or that could have therapeutic implications. Results ...
3 CitationsSource
Purpose: Patients with advanced renal cell carcinoma with sarcomatoid features (sRCC) have poor prognoses and suboptimal outcomes with targeted therapy. This post hoc analysis of the phase III CheckMate 214 trial analyzed the efficacy of nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib in patients with sRCC. Patients and Methods: Patients with sRCC were identified via independent central pathology review of archival tumor tissue or histologic classification per local pathology report. Patie...
31 CitationsSource
Cited By0
Newest